

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



ASKA Pharmaceutical Holdings Co., Ltd.

MICIN and ASKA Enter into Agreement on Joint Development and Marketing of Irritable Bowel Syndrome Treatment App

TOKYO, August 18, 2025 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), announced that ASKA has entered into an agreement on the joint development and marketing of digital therapeutics apps for the treatment of irritable bowel syndrome ("IBS") with MICIN, Inc. (Head Office: Minato-ku, Tokyo/ Representative CEO: Seigo Hara, hereinafter "MICIN").

The impact of this matter on the Company's financial results for the fiscal year ending March 2026 is expected to be minimal.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp

MICIN and ASKA Enter into Agreement on Joint Development and Marketing of Irritable Bowel Syndrome Treatment App

TOKYO, August 18, 2025 – MICIN, Inc. (Head Office: Minato-ku, Tokyo/Representative CEO: Seigo Hara, hereinafter "MICIN") and ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter "ASKA"), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), have entered into an agreement on the joint development and marketing of digital therapeutics apps for the treatment of irritable bowel syndrome ("IBS").

MICIN and ASKA will collaborate to prepare for the product launch. The two companies aim to offer new treatment options in internal medicine by leveraging MICIN's digital therapeutic app development platform and expertise in clinical trial implementation and digital product penetration, as well as ASKA's experience in the medical pharmaceutical business.

< Background and Purpose of the Agreement >

IBS is a functional disorder of the digestive tract characterized by abdominal pain, discomfort, and abnormal bowel movements as its primary symptoms, despite the absence of organic abnormalities such as ulcers or tumors in the large and small intestines. The prevalence of IBS in Japan is about 10%¹, and there are approximately 12 million patients with the disease, many of whom suffer from it as society becomes more complex and stressful. For instance, patients may only ride local trains due to sudden abdominal pain while commuting to work or school, or experience persistent abdominal pain during stressful situations such as important meetings or examinations. This is a serious problem that significantly reduces the patient's quality of life. Therefore, new treatment options are required in addition to existing drug therapies.

MICIN is developing digital solutions such as the telemedicine service "curon" and the decentralized clinical trial (DCT) platform "MiROHA," as well as digital therapeutic apps and treatment support apps that contribute not only to facilitate the management of diseases, but also to prevention, diagnosis, and treatment as part of its digital therapeutics business.

By combining the strengths of MICIN and ASKA through this partnership and offering new treatment options to IBS patients suffering from IBS, the two companies aim to contribute to the development of medical care development.

1. Clinical Practice Guidelines for Functional Gastrointestinal Diseases 2020- Irritable Bowel Syndrome (IBS) Japan Society of Gastroenterology
https://www.jsge.or.jp/committees/guideline/guideline/pdf/IBSGL2020_.pdf

< About MICIN, Inc. >

Company name: MICIN, Inc.
Location: 4F, KDX Nishishimbashi, 3-3-1, Nishishimbashi, Minato-ku, Tokyo
Representative: Representative CEO, Seigo Hara
Business: Telehealth business, decentralized clinical trials business, digital therapeutics business, insurance business, etc.
URL: <https://micin.jp/en/>

< About ASKA Pharmaceutical Co., Ltd.>

Company name: ASKA Pharmaceutical Co., Ltd.
Location: 5-1, Shibaura 2-Chome, Minato-ku, Tokyo
Representative: President, Representative Director, Sohta Yamaguchi
Business: Development, manufacturing, import, export and marketing of pharmaceuticals, quasi-drugs, food supplements, and medical devices.
URL: <https://www.aska-pharma.co.jp/english/>

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp